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Abstract: Rheumatoid arthritis (RA) is an autoimmune disease that affects the joints and results
in reduced patient quality of life due to its chronic nature and several comorbidities. RA is also
associated with a high socioeconomic burden. Currently, several available therapies minimize
symptoms and prevent disease progression. However, more effective treatments are needed due to
current therapies’ severe side-effects, especially under long-term use. Drug delivery systems have
demonstrated their clinical importance—with several nanocarriers present in the market—due to
their capacity to improve therapeutic drug index, for instance, by enabling passive or active targeting.
The first to achieve market authorization were liposomes that still represent a considerable part of
approved delivery systems. In this manuscript, we review the role of liposomes in RA treatment,
address preclinical studies and clinical trials, and discuss factors that could hamper a successful
clinical translation. We also suggest some alterations that could potentially improve their progression
to the market.
Keywords: rheumatoid arthritis; drug delivery nanosystems; liposomes; passive targeting; active tar-
geting
1. Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an immune-mediated chronic inflammatory disease
characterized by chronic inflammation of the joint synovium and progressive joint de-
struction often associated with persistent arthritic pain, swelling and stiffness [1,2]. This
disorder affects 1% of the adult population in Europe and the USA, with an incidence
approximately 75% higher in women than in men [3,4]. The precise cause of RA remains
uncertain, but it is has been generally considered that the crucial factor is an immunological
response against the tissue that lines the joints [1,5,6]. Its chronic progression results in
joint inflammation that can progress to joint destruction. Extra-articular manifestations,
such as rheumatoid nodules and pulmonary vasculitis, can also occur, causing a decline
in the quality and life expectancy of patients and increasing the comorbidity risk (e.g.,
metabolic and psychological disorders) [4,7,8]. Besides individual consequences, there
is also a concomitant socioeconomic burden associated with the medical costs and the
reduced work capability [2,9].
Due to the severe progression of RA, a fast diagnosis is crucial to initiate treatment
before irreversible joint damage might happen [3,10,11]. Nevertheless, a fast differential
diagnosis of RA is difficult to accomplish since symptoms are common to other types of
arthritis or rarer autoimmune conditions, such as connective tissue diseases [9].
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Pathophysiology
The synovial fluid, produced by the synovium, acts as a lubricant in body joints and
supplies cartilage with nutrients and metabolites [12]. In RA, the inflamed synovium
is filled with inflammatory cells both from the innate immune system (e.g., monocytes,
neutrophils, dendritic cells, macrophages, fibroblasts and innate lymphoid cells) and
adaptive immune system (e.g., T-helper cells, B cells, and plasma cells) [9,13]. Upon
activation, inflammatory cells release proinflammatory cytokines (e.g., tumor necrosis
factor α, interleukin-1 and -6) and secrete matrix metalloproteinases and prostaglandins
into the synovial fluid [12]. In sequence, cytokines act as recruiting agents, activating
endothelial cells and enhancing the accumulation of inflammatory cells, with consequent
exacerbation of inflammation in synovial tissues, while secreted matrix metalloproteinases
and prostaglandins cause the degradation of cartilage and bones [13,14] (Figure 1). The
progression of this disease from one arthritic joint to an unaffected joint has been attributed
to activated fibroblasts [15].
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bone erosion; increasing the oxidative stress by production of reactive oxygen or nitrogen species (ROS, RNS respectively)
and recruiting more leukocytes into the joint, exacerbating the inflammation. IL—interleukin; TNF-α—tumor necrosis
factor-alpha.
2. Therapeutic Strategies Used in the Clinic
Since inflammation is the driving force in RA development, its suppression or at-
tenuation is the main therapeutic strategy to improve symptoms, preserve the structural
integrity of the joints and maintain patient quality of life [7]. To date, RA does not have
a cure, and the available drugs are used to attenuate the symptoms and maintain pa-
tients with a functional life [13,16]. To achieve remission, it is crucial to initiate therapy
within three months of disease onset [17]. When RA is in an advanced stage, usually
the goal is not remission but to minimize disease activity/burden [18]. RA drugs are
mainly divided into three classes: (i) nonsteroidal anti-inflammatory drugs (NSAIDs) that
are usually prescribed for management of pain, stiffness and inflammation, improving
patient overall physical function [3,19]; (ii) corticosteroids, also with anti-inflammatory,
anti-angiogenic and immunoregulatory properties, allowing to promote the decrease of
expression of cellular adhesion molecules and cytokines on endothelial cells and thus
preventing joint erosions [20], and (iii) disease-modifying antirheumatic drugs (DMARDs),
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used to prevent joint damage [21]. Personalized treatment decisions should be based on
the number of disease events, and regular follow-up visits may be needed, especially when
RA is active [6]. Nonetheless, efficient predictors of patient response to the different drugs,
according to the disease stage, are still needed [7]. Indeed, NSAIDs are not able to alter the
progression of RA when used alone since they do not interfere with joint damage, and their
long-term use is associated with gastrointestinal, cardiovascular and renal risks [22,23].
Corticosteroids are usually used in the early stages of RA, as temporary adjunctive ther-
apy until DMARDs exert their effects, or as chronic adjunctive therapy when control of
RA is not achieved with the other types of drugs [6,18]. Nonetheless, corticosteroids are
associated with serious long-term side effects, such as osteoporosis, hypertension, diabetes,
obesity, avascular necrosis, growth retardation, cataracts and muscle wasting [24]. When
administered intravenously, they have a rapid clearance and a large distribution volume,
with a higher dosage being necessary for an effective drug concentration at the inflamed
sites [25]. While NSAIDs only control the symptoms, DMARDs decrease the structural
damage progression in joints, being indicated when erosions or narrowing of joints space
in X-rays are visible [21,26]. Currently, DMARDs are the standard drugs prescribed to
newly diagnosed patients, along with NSAIDs or low-dose corticosteroids that decrease
swelling and pain, since DMARDs usually take several weeks or months to demonstrate a
clinical effect [27]. Until the 1980s, the standard DMARDs were gold salts (intramuscular),
which are no longer used, due to their side effects, limited efficacy and slow action [28].
Nowadays, DMARDs can be divided into two main classes: synthetic or biologi-
cal molecules, and these classes can be further subdivided into conventional or targeted
synthetic DMARDs and in the biological originator and biosimilar DMARD [21]. Conven-
tional synthetic DMARDs include sulfasalazine; penicillamine; antimalarials (hydroxy-
chloroquine); gold compounds (auranofin), and immunosuppressors (methotrexate (MTX);
leflunomide; azathioprine; cyclosporin A; cyclophosphamide), while targeted synthetic
DMARDs comprise Janus kinase (JAK) inhibitors (tofacitinib, baricitinib, upadacitinib and
filgotinib) [16,29]. From all the therapeutic options listed above, MTX is considered the
first-line drug for most RA patients due to its high efficacy and the possibility to control its
side effects with the prophylactic use of folates [26,30].
Biological originator DMARDs used in RA treatment can be subdivided into four
classes. The tumor necrosis factor (TNF) inhibitors (etanercept, infliximab, adalimumab,
certolizumab pegol and golimumab) that decrease the inflammatory response; T-cell
costimulatory blocker (abatacept) that interferes with the interactions between antigen-
presenting cells and T cells; the B cell depleting agent (rituximab) that leads to a rapid and
sustained depletion of circulating B cells, reducing RA progression and the interleukin
receptor inhibitors for interleukin-6 (IL-6) (tocilizumab and sarilumab) and interleukin-
1 (IL-1) (anakinra) that decrease inflammation and RA progression [6,31]. The other
group of biological DMARDs includes biosimilars of adalimumab, etanercept, inflix-
imab and rituximab [16]. All the drugs listed in these groups are currently approved
by FDA and EMA, according to their official websites (https://www.fda.gov/ and
https://www.ema.europa.eu/, accessed on 15 February 2021).
Synthetic DMARDs have been associated with some undesirable side effects, namely
in the gastrointestinal system (e.g., vomiting and diarrhea), in the central nervous system
(e.g., headaches, dizziness and insomnia) or damages in skin and hair, while biological
DMARDs can enhance the risk of infections, malignancy, anaphylaxis or autoimmune
syndromes [27]. Biosimilars of some of the previously mentioned biological DMARDs
are in different stages of development or already in the market [27]. For a more detailed
description of the therapeutic recommendations followed by the American College of
Rheumatology, the European League Against Rheumatism, and the Asia-Pacific League of
Associations for Rheumatology consult [16,18,32].
Despite the wide variety of drugs for RA, their benefits are only temporary due
to the off-target toxicity associated with long-term use [1]. This drawback is especially
important when there is a systemic administration because of unfavorable pharmacokinetic
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properties (rapid clearance rate and unspecific distribution profile) that lead to more
frequent administrations of high doses [33]. When only a couple of joints are affected by
RA, or when they do not present a satisfactory response to the systemic administration,
clinicians can use intra-articular injections as an alternative route, increasing local drug
concentration in joints, minimizing the necessary doses and off-target side effects [34,35].
Additionally, these injections improve the delivery of therapeutic agents with low oral
bioavailability, such as proteins and genetic material [34]. However, the intraarticular route
has the drawback of rapid clearance of the injected agent, which leads to a higher frequency
of joint needling, resulting in infection, joint disability, post-injection flare and intolerance
of the patients [27].
Tapering Therapy in Remission
With all the therapeutic strategies previously listed, RA remission is a more attainable
goal—mainly when RA is in an early-stage, and the therapy starts soon after the onset of
the disease [17]. The management of these patients is crucial to assure that no regression
into an active RA is observed [36]. Currently, treatment guidelines suggest that clinicians
should consider tapering therapy [16,18].
3. Biomarkers for Active Targeting in Rheumatoid Arthritis
A wide variety of targets have been explored for RA therapy associated with the vast
number of factors involved in the inflammation of the synovial fluid. One of them is the
folate receptor (FR-β) that is overexpressed in synovial macrophages of the inflamed joints.
The ease chemical conjugation of folate to other molecules through the γ-carboxyl group al-
lows the development of folate conjugates that are internalized through receptor-mediated
endocytosis [37]. Other studies have identified the CD44 receptor (also overexpressed in
the synovial lymphocytes, macrophages and fibroblasts of RA patients) as a possible target
via conjugation with its ligand: hyaluronic acid [38].
Angiogenesis is of extreme importance in chronic inflammatory diseases: the newly
formed blood vessels, a consequence of local hypoxia and growth factor production at
inflamed joints [39], allow the permeation of the inflammatory cells into the inflamed
tissue [40]. Furthermore, it is known that angiogenic factors stimulate the expression of
adhesion molecules and inflammatory cytokines and chemokines in endothelia [41]. Within
the angiogenic factors, αvβ3 integrins and vascular endothelial growth factor (VEGF)
have been studied as therapeutic targets in RA. αvβ3 integrins are cell surface receptors
expressed in the newly formed blood vessels in the RA synovium [39]. These integrins are
essential in synovial angiogenesis, making them a potential target for RA treatment through
their blockage [42]. Besides integrins, VEGF and its receptors also stimulate vascular
permeability and angiogenesis and are overexpressed in inflammation [41,43,44]. Due to
their crucial role, VEGF and its receptors are the best-characterized systems responsible for
angiogenesis regulation in rheumatoid joints, making them great potential targets [45].
Among the cellular adhesion molecules, selectins are important in RA due to their role
in the recruitment of leukocytes into synovial tissues [46]. Similar to the other targets men-
tioned above, selectins are also overexpressed in inflammatory cells and can be subdivided
into P-selectins, E-selectins and L-selectins, according to the type of cells where they are
expressed [46]. The E-selectins are upregulated in inflammation [46,47], and its blockage
would be a useful strategy in RA treatment. Other therapeutic targets for RA therapy may
include specific antigens differentially expressed on the surface of activated macrophages,
such as CD163 [48], or components involved in immune cell activation, such as Bruton’s
tyrosine kinase B that is involved in B cell activation [49]. Additional information of other
targets may be consulted in [14,50].
4. Drug Delivery Nanosystems
Drug delivery systems appeared as a strategy to partially overcome the hindrances
presented by conventional therapies, including the difficulty in crossing biological barriers
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and the incapacity of an active form of the therapeutic compound to achieve its target,
either because of an early degradation or interaction with other molecules [51]. With
drug delivery, it is possible to improve the pharmacokinetic and pharmacodynamic of
a compound, decreasing the required dose and side effects, ultimately maximizing the
therapeutic index [52].
Within drug delivery, nanosystems gained a major role as a therapeutic option, being
currently explored for most of the pathologies. They can be divided into non-viral and viral
vectors and, according to their properties, can be administered locally or systemically by
several administration routes, such as intravenous (i.v.), intraperitoneal (i.p.); intra-articular
(i.a.); intramuscular (i.m.); subcutaneous (s.c.); epicutaneous (e.c.); oral; ocular; nasal and
transdermal administration.
From all the types of drug delivery nanosystems (nanoDDS), liposomes were the
first that received market authorization in 1995, and currently are still a significant part of
nanoDDS under investigation—being present in all stages of clinical development—and
represent 20% of the nanoDDS in the market [53–55]. A detailed revision of liposomal
formulations, either in clinical trials or in the market, can be consulted in Bulbake et al. [53].
4.1. Liposomal Formulations Developed for Rheumatoid Arthritis Treatment
New therapeutic strategies that use drug delivery nanosystems targeted to arthritic
joints have been under investigation. In pathologies that affect a limited number of sites
that are easily accessible, local administration routes play an important role [33,34]. In
the case of RA, nanocarriers (e.g., liposomes, nanoparticles and hydrogels) have been
administered by intra-articular (i.a.) route to decrease drug clearance and enhance patients
compliance [50]. One of the latest examples is a conventional liposomal formulation that
incorporates a prodrug of sulfapyridine, an active metabolite of sulfasalazine responsible
for systemic side-effects [56]. This nanocarrier, upon i.a. administration on a complete
Freund’s adjuvant-induced arthritis (CFA) rat model, demonstrated a significant reduction
in the joint diameter, paw volume, pain threshold and in plasma and serum levels of
biomarkers (IL-6, tumor necrosis factor-alpha (TNF-α), alkaline phosphatase (ALP), alanine
transferase (ALT), aspartate aminotransferase (AST) and rheumatoid factor (RF) [57].
NanoDDS have also proven their efficacy as an optimized approach for systemic
administration. These carriers can passively accumulate in arthritic joints through the EPR
effect, enhancing drugs’ therapeutic effectiveness [58]. In addition to the passive targeting,
successful delivery of nanosystems could be achieved via active targeting strategies. In
this approach, functional and cellular changes that exist in arthritic joints are explored, for
instance, through the targeting of macrophages, fibroblasts and angiogenesis [5,14].
Similar to the classification applied for conventional therapies, nanoDDS developed for
RA treatment can also be subdivided into several classes: nonsteroidal anti-inflammatory
drugs, glucocorticoids, disease-modifying antirheumatic drugs and biologic agent delivery
nanosystems. Additionally, new molecules that are not included in the conventional
therapies were explored in nanocarriers, such as compounds used in traditional Chinese
medicine and natural compounds with reported anti-inflammatory effects [59,60]. For
each of the previously mentioned classes, several types of nanoDDS were developed
and evaluated in vitro and in vivo, displaying a therapeutic benefit in RA models. Due
to the countless studies reported involving delivery nanosystems in RA and the major
role of liposomes as an alternative therapeutic strategy—with a considerable presence
in preclinical and clinical stages, as well as in the market—only this type of nanocarrier
is exemplified in Table 1 and will be further discussed. Over the years, some reviews
have been published either reporting several types of nanoDDS or focusing on a specific
nanocarrier for RA treatment, including [33,50,61–64]. Concerning liposomal formulations,
this manuscript reviews the data available until February 2021.
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Table 1. Examples of liposomes developed for rheumatoid arthritis treatment divided according to the therapeutic agent used. The lipid composition, the corresponding molar ratio and
the mean diameter were indicated for each liposomal formulation.
Therapeutic Agent Drug Delivery Nanosystems Developed Lipid Composition(Molar Ratio) Diameter (nm) Reference
Nonsteroidal
Anti-inflammatory Drug
Liposomes with incorporated indomethacin SL:Chol:SA/DCP (7:3:1) n.r. [65]
EPC:Chol:SA/PG (1:0.5:0.1/0.2) 50 or 100 [66]
Liposomes with incorporated celecoxib Lipova E120:Chol: DSPE-PEG2000 (9:1:0.25) 92 [67]
Gel formulation of liposomes with encapsulated diclofenac sodium DMPC:Chol:DCP (7:1:2) 235 [68]
Oil/water emulsion of liposomes with incorporated diclofenac EPC:DCP (9:1 or 7:3) 4430–5400 [69]EPC:Chol (9:1 or 7:3) 3590–4280
Glucocorticoid
Liposomes with encapsulated prednisolone phosphate 1 DPPC:Chol:DSPE-PEG2000 (1.85:1:0.15) 90–110 or 450–500 [25,70–73]
Liposomes with encapsulated methyl prednisolone hemisuccinate HSPC:Chol:DSPE-PEG2000 (55:40:5 or 54:41:5) 68–98 [74,75]
Poly-(hydroxyethyl L-asparagine) (PHEA)-liposomes with
encapsulated prednisolone phosphate DPPC:Chol:PHEA-DODASuc (1.85:1.0:0.15) 144–148 [76]
pH-sensitive liposomes with incorporated prednisolone, targeted
with hyaluronic acid DPPE:CHEMS (6.5:3.5) 113–119 [77]
Liposomes with encapsulated prednisolone phosphate, targeted with




Liposomes with encapsulated dexamethasone phosphate DPPC:Chol:DSPE-PEG2000 (1.85:1.0:0.15) 90–100 [73]
DPPC:DPPG:Chol (50:10:40) 280–310 [79–81]
Liposomes with incorporated dexamethasone SPC:Solutol HS 15 (3:1) 60 [82]
Polymerized liposomes with incorporated dexamethasone DC8,9PC:DSPE-PEG2000 (9:1) 112–131 [83]
Liposomes with incorporated dexamethasone palmitate, targeted
with sialic acid
HSPC:Chol (55:40) 130–138 [84]
DSPC:DSPG:Chol (8.9:2.4:1) 71–79, 146–154 or295–305 [85]
Liposomes with incorporated dexamethasone palmitate, targeted
with mannose DSPC:Chol (60:35 or 60:32.5) 142–146 or 176–190 [86,87]
Liposomes with encapsulated dexamethasone sodium phosphate,
targeted with folate (FA) DPPC:Chol:DSPE-PEG2000-FA (64:30:5) 157–159 [88]









Liposomes with encapsulated betamethasone hemisuccinate HSPC:Chol:DSPE-PEG2000 (55:40:5 or 54:41:5) 68–98 [74,75]
Liposomes with encapsulated betamethasone, targeted with folate DSPC:Chol:DSPE-PEG2000:DSPE-PEG3400-FA (56:40:4:0.1)
90–110 [90]
Liposomes with encapsulated budesonide phosphate DPPC:Chol:DSPE-PEG2000 (1.85:1:0.15) 90–100 [73]
Liposomes with incorporated triamcinolone acetonide DPPC:Chol:PA (8:3:1) n.r. [91]
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Table 1. Cont.
Therapeutic Agent Drug Delivery Nanosystems Developed Lipid Composition(Molar Ratio) Diameter (nm) Reference
Disease-modifying
Antirheumatic Drug
Liposomes with encapsulated methotrexate sodium salt
EPC:Chol:DCP (5:5:1) 1070 [92,93]
EL:Chol:PA (7:2:1) 100 [94]
DOPE/EPC:Chol:DSPE-PEG2000 (54:36:10) 121–136/194–208 [95]
Liposomes with incorporated methotrexate EPC:Chol:PA (7:2:1) orDSPC:Chol:DSPE-PEG2000 (10:5:1)
100 [96,97]
EL:Chol:PA (7:2:1) 100 or 1200 [98,99]
POPC:Chol:DMPA 1200 [100]
Liposomes with encapsulated methotrexate, targeted with folate DOPE:Chol:DSPE-PEG2000-CA (n.r.) 120 [101]
Liposomes with incorporated methotrexate, targeted with mannose DSPC:Chol (60:35) 122–127 [102]
Echogenic liposomes containing methotrexate and indocyanine green,




Liposomes with co-encapsulated methotrexate and catalase, targeted
with folate POPC:Chol:S100-FA (13.2:1.9:0.6) 141–150 [104]
Liposomes with encapsulated tofacitinib citrate SPC:Chol (1:1) 55–63 [105]
Liposomes with incorporated sulfapyridine or an amide prodrug
of sulfapyridine P-90G:Chol (6.3:3.1 or 5.5:4.7) 455–470 or 762–930 [57]
Biologic Agent
Liposomes with encapsulated or covalently linked
superoxide dismutase
EPC:Chol:SA (7:2:1) 90, 110 or 210





Liposomes linked to tumor necrosis factor-related apoptosis-inducing
ligand (Apo2L/TRAIL) EPC:SM:Chol:DGS-NTA (7.1:3.9:2.6:0.5) 150–200 [111]
Liposomes encapsulating siRNA for TNF-α, IL-1β, IL-6 or IL-18 DOPE:RPR209120:carrier DNA (n.r.) 1500–2000 [112,113]
Liposomes containing miR-23a/polyethylenimine (PEI) complex DSPC:DSPE-PEG2000 (n.r.) 104–109 [114]
Liposomes encapsulating human lactoferrin DPPE:Chol:SA (5:5:1) 200 [115]
Liposomes with anti-IL-23 antibody covalently linked to the surface,
containing gold nanoparticles EPC:Chol:DSPE-PEG2000-Mal (0.85:1:0.15) 127–133 [116]
Liposomes with encapsulated IL-27, targeted with ART-1 lipopeptide DOPC:DOPE:Chol: DSPEPEG2000-NH2(1:0.5:0.5:0.01) 92–95 [117]
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Table 1. Cont.





Double liposomes with encapsulated prednisolone and incorporated





Liposomes with co-encapsulated methotrexate and calcium





Liposomes with incorporated dexamethasone and co-encapsulated
nuclear factor-κB (NF-κB) decoy oligodeoxynucleotides and gold





Liposomes with incorporated berberine DSPC:Chol:DSPE-PEG2000 (60:35:2.5) 157–161 [114]
Liposomes with incorporated dimethyl curcumin SPC:Chol (1.3:2.6) <200 [121]
Liposomes with encapsulated clodronate PEG400-S:Chol:SDS (1.8:1.8:0.45) 858–942 [122]
EPC:Chol:DPPA (7:7:1) 100
[123,124]EPC:Chol (2:1) n.r.
EPC:Chol (n.r.) 120–160 [125]
DSPC:DSPG:Chol (n.r) n.r. [126]
Thermosensitive liposomes with encapsulated sinomenine
hydrochloride DPPC:SPC:Chol (5.1:1.6:0.7) 111–121 [59]
Hydrogel patch containing liposomes with incorporated triptolide EL:Chol (2.9:1.2) 183–220 [60]
Dimeric artesunate phospholipid-conjugated liposomes Di-ART-GPC 70–83 [127]
Liposomes with incorporated naringin and encapsulated
sulforaphane or phenethyl isothiocyanate DPPC:Chol:DSPE-PEG2000 (15:4:1) 147–159 [128]
Liposome/gold hybrid nanoparticles containing coenzyme Q10 DSPC (n.r.) n.r. [129]
Liposomes with incorporated morin, targeted with mannose DSPC:Chol (60:35) 127–137 [86]
Liposomes with incorporated p-coumaric acid, targeted with mannose DSPC:Chol (60:35) 114–124 [102]
Liposomes with incorporated withaferin-A, targeted with mannose DSPC:Chol (60:32.5) 150–155 [87]
Liposomes with encapsulated or incorporated core peptide, targeted




1 Advanced to clinical trials (NIH identifier indicated in Section 5.1). n.r.—non-reported in the study.
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Several parameters are important for the characterization of liposomal systems, such
as (i) the preparation method, (ii) the lipid composition, (iii) the ratio between the lipids
and between the total lipid and the therapeutic compound used during the preparation,
(iv) the mean diameter and polydispersity index (PDI), (v) the superficial charge (ζ), (vi)
the incorporation/encapsulation efficiency (further referred as E.E.) and (vii) the loading
capacity (L.C.). However, most of the studies only provide part of this information, namely
the lipid composition with the respective ratio, the mean diameter and the E.E. obtained. As
the last parameter is dependent on the initial concentration of drug—decreasing when drug
concentrations are closer to the liposomal saturation limit—its use for comparison purposes
is only adequate when the same drug-to-lipid ratio is used between different formulations.
A more reliable factor in comparing nanocarriers is the loading capacity (µg drug/µmol
lipid) obtained, but only a small number of studies present this information. For this reason,
only the lipid composition, the respective molar ratio and the mean diameter are shown in
Table 1. The other parameters will be further detailed in the description of the nanosystems
when available.
Among the cases where E.E. is a useful parameter for liposomal evaluation are in-
cluded studies, such as the one performed by Guimarães et al. [95] where the ethanol
injection method was compared to the preconcentration method—a modified version of
the former that was developed in this study—resulting in the enhancement of E.E. su-
perior to 30%, without the requirement of the extrusion process, or the study of Srinath
et al. [66] where four preparation methods were compared and, in each one, five different
lipid compositions were evaluated. From the results obtained, the authors observed that
the incorporation of indomethacin was higher in multilamellar vesicles (MLVs) than in
large unilamellar vesicles (LUVs), with the thin-film hydration method being the one that
resulted in the highest E.E. for all lipid compositions. Moreover, the inclusion of charged
lipids, such as stearyl amine and phosphatidylglycerol, decreased in vitro drug release and
reduced in vivo paw edema, resulting in a higher anti-inflammatory effect. Nonetheless,
this study could be improved by: (i), including a complete characterization of liposomal
formulations, such as the mean size of MLVs and LUVs; (ii) performing the comparison of
E.E. in small unilamellar vesicles (SUVs)—whose therapeutic effect was assessed in RA
models—instead of in MLVs and LUVs; (iii) avoiding the compartmentalized comparisons
between liposomal formulations without, including the one with the highest E.E.
Table 1 shows that cholesterol is frequently used in formulations, followed by phos-
phatidylcholine and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polye-
thylene glycol)-2000] (DSPE-PEG2000). This may be related to their role in liposomal
formulations. Indeed, cholesterol can alter the packing of lipid chains, modulating mem-
brane fluidity and permeability; phosphatidylcholine has a structural role and is one of
the main constituents of biological membranes, and PEG-lipid conjugates confer long-
circulating properties to liposomes [130]. In other studies, distinct lipids were used for
a specific purpose, such as 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and
cholesteryl hemisuccinate (CHEMS) due to their pH-sensitive properties, and RPR209120
cationic lipid for genetic material delivery [131].
Moreover, most nanocarriers from Table 1 display a mean diameter under 200 nm.
This feature is generally used for i.v. administration of nanoDDS, the major administration
route explored for RA, and enable nanocarriers accumulation in inflamed joints either by
passive targeting, mainly when PEG-liposomes were used, or by active targeting when PEG-
liposomes were functionalized with targeting agents. Additionally, when larger liposomal
formulations were investigated, i.a. administration was the most employed, resulting in an
enhanced anti-inflammatory effect [57,93,98]. Nevertheless, i.v. the administration was also
described in studies where the effect of larger and smaller liposomes effect was compared,
resulting in a higher therapeutic benefit of smaller nanocarriers, either when passive or
active targeting strategies were applied [25,85].
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4.1.1. Liposomes Containing Nonsteroidal Anti-Inflammatory Drugs
From the division performed in Table 1, NSAID is the class of therapeutic agents that
have been less investigated for liposomal drug delivery—only three distinct drugs were
explored. This fact is possibly related to the minor role that NSAIDs have in RA from a
therapeutic perspective: these drugs are incapable of protecting joints from damage; they
only mitigate symptoms.
From the two liposomal formulations with indomethacin developed for systemic
administration, one was studied in a carrageenan-induced rat paw edema model, where
the inhibition of paw edema was observed [65], and in the other, indomethacin-loaded
liposomes (E.E.: 28–46%) have proven to be more effective in reducing joint inflammation
than free drug in both carrageenan-induced paw edema and Freund’s adjuvant arthritis
rat models, as well as in reducing ulcers severity [66].
Intra-articular and transdermal administration routes also proved to be useful in
RA treatment. In the first, a single i.a. injection of a gel formulation of diclofenac lipo-
somes resulted in the reduction of joint swelling in antigen-induced arthritis (AIA) rabbit
model [68], that has the advantage of being a chronic model of RA, where the destruction
of cartilage and bone occurs, contrary to the carrageenan and Freund’s adjuvant arthritis
models [132]. In the second, an emulsion containing diclofenac liposomes (E.E.: 14–23%)
was topically administered, and ultrasounds were used to enhance skin permeation in
a carrageenan-induced rat paw edema model, resulting in a high suppression of paw
inflammation [69].
4.1.2. Liposomes Containing Glucocorticoids
To improve their therapeutic effectiveness, glucocorticoids also have been included
in nanosystems for distinct routes of administration. Within the i.a. route, liposomes
incorporating triamcinolone acetonide-21-palmitate in their membrane showed enhanced
drug retention in the articular cavity, as well as a reduction of the presence of inflammatory
cells in the joints and a decrease in paw edema of arthritic rabbits when compared to the
free drug [91]. Most studies reported for glucocorticoids in Table 1 were designed for
i.v. administration, where dexamethasone was the most investigated drug for liposomal
delivery—possibly due to its higher potency [133]—followed by prednisolone.
All the developed liposomal formulations of dexamethasone resulted in a higher
therapeutic effect than free dexamethasone [79,82,83], being capable of a higher reduction
in joint swelling, inflammation and destruction, even when a lower drug dose was used
in liposomes [80,81]. Additionally, liposomal dexamethasone (PDI: ≤0.3, L.C.: 40 µg
drug/µmol lipid) demonstrated its efficacy for longer periods, where free dexamethasone
no longer presented a therapeutic effect, revealing its potential as a strategy to minimize
administration frequency and avoid side-effects [81]. A similar dose-reduction effect was
observed with prednisolone liposomes (L.C.: 58–75 µg drug/µmol lipid), where a single i.v.
administration of liposomes caused remission of joint inflammation, along with a reduction
of cartilage damage similar to the one obtained with multiple administrations of a ten times
higher dose of free prednisolone, in two distinct models: murine collagen-induced arthritis
(CIA) [72] and a rat AIA model [25]. Additionally, these liposomes were able to minimize
bone erosion [70,71] and reverse the disease-induced weight loss [25,72]. Due to the
promising therapeutic effect obtained with this nanocarrier, prednisolone PEG-liposomes
have advanced to clinical trials (NIH identifiers indicated in Section 5.1).
Another strategy explored to further decrease the administered dose was the use of
liposomes with glucocorticoid prodrugs that exhibit a lower clearance than the active form.
In this case, two glucocorticoids—methylprednisolone hemisuccinate and betamethasone
hemisuccinate—were evaluated in RA treatment. Liposomes encapsulating each of these
two prodrugs (E.E.: 94%) resulted in a higher therapeutic effect than the free glucocor-
ticoids in an AIA rat model, even when liposomes were injected with lower doses [74].
Moreover, a significant reduction in RA severity throughout early and late disease stages
was observed. In another study, the effect of these two nanoformulations, upon i.v. or
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s.c. The administration was compared to weekly or daily treatment with the free drugs or
with two biological DMARDs—infliximab and etanercept. The results obtained showed
that liposomes of both prodrugs (E.E: >90%, drug-to-lipid molar ratio: >0.35) significantly
suppressed arthritis in an AIA rat model, reducing the arthritis score and inhibiting the
production of proinflammatory cytokines, either compared to higher doses of the free
drugs or biologic DMARDs [75].
Besides the passive targeting strategy previously described for glucocorticoid delivery,
active targeting approaches have also been investigated for RA treatment, with systemic
delivery of liposomes. In the case of dexamethasone, five distinct targeting agents were
used, namely sialic acid, folate, mannose, RGD peptide and ART-2 lipopeptide (Table 1).
The last two agents target nanocarriers for endothelial cells in the blood vessels at the
inflamed synovium, whereas folate and mannose target them to macrophages, and sialic
acid targets them to peripheral blood neutrophils. Overall, all the liposomal formulations
demonstrated a therapeutic benefit in comparison to the non-targeted liposomes or free
drugs. In dexamethasone nanocarriers targeted with RGD (PDI: 0.1, E.E.: 3–6%; L.C.: 30–
60 µg drug/µmol lipid) or ART-2 (PDI: 0.3, ζ: 40 mV, E.E.: 73–78%) peptides, a prolonged
anti-inflammatory effect was observed in arthritic rats [20], resulting in an enhanced
efficacy without increasing the adverse side-effects [89]. Sialic acid-targeting resulted in
the inhibition of RA progression by dexamethasone liposomes (PDI: 0.2, ζ: −16 to −21 mV,
E.E.: 90–95%), with a decrease in proinflammatory cytokines and transaminase levels [84].
Interestingly, the effect of three distinct sizes of liposomes (300 nm, 150 nm and 75 nm—
PDI: <0.2, ζ: −39 mV, E.E.: 97–98%) was compared, and the smallest liposomes were the
ones that resulted in the higher suppression of paw thickness and reduction of arthritis
scores, proinflammatory cytokines and transaminase levels [85]. Nonetheless, arthritic rats
treated with all the sialic acid-targeted dexamethasone formulations exhibited a significant
reduction in joint injury and pathological score in comparison to the free drug [85].
A distinct approach was used with dexamethasone liposomes targeted with folate,
where the effect of a combined therapy among liposomes, microbubbles and ultrasounds
was assessed [88]. This study demonstrated that folate-targeted liposomes (ζ: −3 mV, E.E.:
9–10%) resulted in a therapeutic benefit when compared to non-targeted liposomes and
free dexamethasone. However, the therapeutic effect of folate-targeted liposomal dexam-
ethasone was even higher when the treatment included the destruction of microbubbles
with ultrasounds, demonstrating a synergistic effect. The combination of both strategies
resulted in a greater decrease in inflammatory cytokines; an inhibition of joint swelling,
with reduced joint synovial hyperplasia and infiltration of inflammatory cells; and in the
protection against cartilage damage and bone erosion in a rat CIA model [88].
With prednisolone liposomes, only one of the three targeting agents used was common
to the ones used with dexamethasone—RGD peptide—the others were HAP-1 peptide and
hyaluronic acid that targeted liposomes to fibroblast-derived type B synoviocytes or to
synovial cells, respectively. The targeting of prednisolone liposomes also improved disease
outcomes after the treatment compared to non-targeted liposomes [78]. In the study of
Vanniasinghe et al. [78], a direct comparison of the targeting effect of RGD and HAP-1 in
prednisolone liposomes (PDI: <0.4, ζ: −16.2 to −24.0 mV) was performed, where it was
possible to observe that, despite both being capable of decreasing RA severity in an AIA
rat model, HAP-1 resulted in a higher survival rate and enable a decrease in the necessary
dose for a therapeutic effect, highlighting its superior potential as a targeting agent in
RA treatment.
Besides comparing targeting agents, comparison of nanocarriers with distinct drugs
is also crucial since they enable the direct evaluation of which one has the most potential
to be a good alternative in RA therapy. Despite their utility, these types of studies are not
common. An example is a comparative study performed to access the therapeutic efficacy
of liposomes with three distinct glucocorticoids (L.C.: 58–75 µg drug/µmol lipid), namely
prednisolone disodium phosphate, dexamethasone disodium phosphate and budesonide
disodium phosphate [73]. The authors observed that among the three, budesonide lipo-
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somes were the most promising candidates for glucocorticoid liposomal formulations since
they induced a full remission of clinical arthritis signs in a shorter time, with a lower dosage
and with minimum adverse side-effects.
4.1.3. Liposomes Containing Disease-Modifying Antirheumatic Drugs
Within DMARDs, methotrexate has been the most studied drug for liposomal delivery,
either using passive or active targeting strategies. The first attempt to encapsulate this
drug in liposomes was made in 1988 by Foong and Green for i.a. administration in arthritis
rabbits [92]. A higher accumulation of methotrexate at the joint was obtained, and the
formulation (L.C.: 10 µg drug/µmol lipid) was able to suppress arthritis development if
injected at the time of disease induction, even at a lower dose, comparatively to the free
drug. However, neither free nor liposomal DMARD were able to suppress established
arthritis [93]. Later, the i.v. administration of methotrexate liposomes was also studied in
a CIA rat model, where an improved anti-inflammatory activity, with a decrease in paw
edema and arthritis score, was observed in the short-term for conventional liposomes and
in the long-term for PEG-liposomes [96,97].
Active targeting of methotrexate liposomes was performed with folate, mannose and
iRDG peptide. In the first, an i.p. administration of these liposomes in a murine CIA model
caused a higher accumulation in the inflamed joints with an increased internalization
in activated macrophages, being capable of avoiding the development of arthritis when
applied as a prophylactic treatment, in contrary to the non-targeted formulation or free
methotrexate [101]. In iRGD active targeting, the combination of echogenic liposomes (PDI:
0.2, ζ: −6 to −14 mV, E.E.: 69%) and ultrasounds were explored, resulting in dexametha-
sone release from liposomes induced by low-frequency ultrasounds [103]. In this study, a
higher therapeutic effect was obtained when liposomes and ultrasounds were combined as
a therapy, in comparison with all the other groups—free drug, targeted liposomes without
ultrasounds and non-targeted liposomes with ultrasounds. The reduction of arthritis score
and inflammatory cell infiltration, along with the absence of cartilage and bone destruction,
were preferentially observed when the combinatory therapy was applied in a murine CIA
model. Additionally, the simultaneous inclusion of indocyanine green in iRGD-targeted
dexamethasone liposomes enabled near-infrared fluorescence imaging, demonstrating the
potential of this nanocarrier as a theranostic agent.
Another nanoDDS with triggered methotrexate release is a folate-targeted liposomal
formulation (PDI: 0.2, ζ: −4 mV, E.E.: 84–89%) that co-encapsulated methotrexate and
catalase, an enzyme that converts hydrogen peroxide in oxygen and water. Since high levels
of intracellular ROS are observed in activated macrophages existent in RA, when liposomes
are internalized by these cells, oxygen is produced, leading to the destruction of the
liposomal membrane with a consequent release of methotrexate [104]. This system resulted
in the enhancement of the therapeutic efficacy with minimal toxicity and maintenance
of body weight when compared to free or liposomal methotrexate and to non-targeted
liposomes with both compounds in a CIA rat model.
The investigation in targeted delivery nanosystems for biologic DMARDs is only in the
beginning, with minimal numbers of nanoDDS developed. The only example reported in
Table 1 is tocilizumab encapsulated in liposomes (PDI: 0.2, ζ: −2 mV, E.E.: 86%) that, upon
i.v. administration demonstrated an improved therapeutic effect in comparison with free
tocilizumab, with a higher reduction in paw edema, arthritis joint score, proinflammatory
cytokine expression, and bone erosion in arthritic rats [105].
4.1.4. Liposomes Containing Biologic Agents
The first biologic agents used in therapy were proteins, such as superoxide dismutase
(SOD), an enzyme with an anti-inflammatory activity that catalyzes the dismutation of
superoxide radicals (O2•−) to molecular oxygen (O2) and hydrogen peroxide (H2O2) [134].
This enzyme was first encapsulated in liposomes in 1985, and a higher therapeutic effect
was achieved with reduced toxicity in RA [110]. Later, SOD was encapsulated in distinct
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liposomal formulations (PDI: <0.4, L.C.: 12–15 µg SOD/µmol lipid), and it was possible to
observe that after i.v. [108] or s.c. [106] administration in an AIA rat model, smaller PEG-
liposomes (PDI: <0.1, L.C.: 12–15 µg SOD/µmol lipid) were more efficient in delivering
SOD to arthritic sites, resulting in a concomitant stronger paw edema reduction.
In another study, the effect of SOD localization in liposomes was evaluated by com-
paring conventional SOD that was encapsulated in liposomes with an acylated SOD that
was incorporated in the liposomal membrane. Liposomes with acylated SOD (PDI: <0.2,
L.C.: 3–9 µg SOD/µmol lipid) showed a faster onset of anti-inflammatory activity, possibly
because there is no need to release the enzyme since it is partially exposed at liposome
surface [107]. In 2015, a different approach was studied, where SOD was covalently linked
to the surface of long-circulating liposomes (L.C.: 50–60 µg SOD/µmol lipid). After i.v.
administration in an AIA rat model, this formulation showed higher anti-inflammatory
activity than liposomes with encapsulated SOD, demonstrating that not only the inclusion
of drugs in nanocarriers but also their location in them could have a significant impact on
the therapeutic outcome [109].
Besides enzymes, other proteins, such as human lactoferrin, cytokines and antibodies,
were also explored as a therapeutic strategy in RA [111,115,116]. An example is a liposomal
formulation containing a cytokine capable of inducing apoptosis, named Apo2 ligand or
tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL), that was injected
i.a. in the inflamed joint space in an AIA rabbit model [111]. In this study, a reduction of
synovial hyperplasia until nearly the normal value was obtained and joint inflammation
was reduced by 60% after liposomal treatment, compared to a 30% decrease with the
free cytokine.
Active targeting strategies have also been applied in liposomes with cytokines. In
this case, IL-27 liposomes (PDI: 0.1, ζ: 19–37 mV, E.E.: 38–41%) were targeted with ART-1
lipopeptide to synovial endothelial cells [117]. This nanocarrier resulted in higher suppres-
sion of RA progression in an AIA rat model that non-targeted IL-27 liposomes or free IL-27,
with a significant decrease in transaminases levels, cartilage damage and bone erosion.
A distinct approach, which also involves cytokines, is a liposomal formulation con-
taining gold nanoparticles and with anti-IL-23 antibody covalently linked to the liposomal
surface (PDI: 0.1, ζ: −24 mV, E.E.: 74–90%). This system enables the capture and inacti-
vation of IL-23, a proinflammatory cytokine, potentially attenuating inflammation and
immune cell recruitment in RA [116].
Further to the use of proteins, the therapeutic effect of genetic material is also signifi-
cantly improved with the use of nanocarriers since when used alone, they present a short
biological half-life [135,136]. In the last decade, gene therapy has been successfully trans-
lated to clinics in other pathologies, which motivated more investigation in this area. In RA,
silencing RNA was investigated upon i.v. administration in a murine CIA model, namely
through liposomal formulations encapsulating siRNA for TNF-α (ζ: 30–40 mV) or for IL-1β,
IL-6 or IL-18, individually. The former allowed a complete inhibition of experimentally
induced arthritis with a decreased TNF-α secretion by 50–70% [112]; the latter delayed
RA onset and progression through the inhibition of joint swelling and bone destruction
for siRNA of all interleukins used individually. Using simultaneously formulations of the
three interleukins (1β, 6 and 18) siRNAs resulted in a notable therapeutic effect, where
was achieved a decrease in inflammation and joint destruction comparable to the obtained
with TNF-α siRNA liposomes [113]. More recently, gene silencing has been explored by
targeting gene regulators, such as microRNAs, that also benefit from their inclusion in
nanoDDS. One example of microRNA that has been explored in RA treatment is a liposo-
mal formulation (PDI: 0.1, ζ: 30 mV) that contained a complex between microRNA-23a
and polyethylenimine [114]. With this system, it was possible to observe a reduction of
paw edema, cartilage degradation and bone damage in comparison to non-treated animals
in an AIA rat model. Additionally, the infiltration of inflammatory cells in joints and
proinflammatory cytokines expression also decreased, while the RA-induced loss of body
weight was partially recovered, demonstrating a therapeutic benefit.
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4.1.5. Liposomes Containing a Combination of Distinct Therapeutic Compounds
Besides the use of a therapeutic agent by itself in liposomes, some studies investi-
gated the effect of a combination of drugs from distinct classes. In these more complex
systems, active targeting with folate was used as a strategy to enhance even more the
treatment outcome. For instance, a glucocorticoid and a DMARD, namely prednisolone
and methotrexate, were simultaneously loaded in a liposomal formulation (PDI: 0.1, ζ:
8 mV, E.E.: 62–71% for prednisolone and 44–47% for methotrexate) targeted with folate and
their effect after i.v. administration in a rat model of RA was assessed [118]. In comparison
to a mixture of individual free drugs and to non-targeted liposomes with both drugs,
the active targeting of liposomes with folate resulted in a higher drug concentration in
joints and consequently in the highest inhibition of paw edema, demonstrating a greater
therapeutic potential.
In another study, a more complex carrier was developed, namely folate-targeted lipo-
somes (ζ: −24 mV) co-encapsulating methotrexate and calcium phosphate nanoparticles
that contained p65 siRNA [119]. In this study, targeted liposomes with the DMARD and
siRNA demonstrated a superior effect in reducing paw edema and arthritis score in a
murine CIA model than the groups that were i.v. injected with naked p65 siRNA, free
methotrexate or non-targeted liposomes containing both compounds. Interestingly, while
free methotrexate was able to attenuate paw edema, naked siRNA was not able to pro-
duce any therapeutic benefit, demonstrating the impact that nanosystems have in genetic
material delivery.
Dexamethasone was also evaluated in a very complex nanoDDS, composed of folate-
targeted liposomes that incorporated dexamethasone and co-encapsulated nuclear factor-
κB (NF-κB) decoy oligodeoxynucleotides (ODNs) and gold nanorods (GNRs) (PDI: 0.2,
ζ: −13 mV, E.E.: 50% for dexamethasone and 36% for ODNs/GNRs) [120]. This carrier
was designed to have a triple therapeutic effect in RA that culminates in the inhibition of
the NF-κB inflammatory pathway. The individual contribution of each component was
the following: (i) dexamethasone exerted the anti-arthritic effect previously described
for corticosteroids in Section 2; (ii) ODNs inhibited the interaction of p50/p65 proteins
with inflammatory gene sequences, partially inhibiting the NF-κB pathway; and (iii) GNRs
released heat upon near-infrared laser irradiation, accelerating the destruction of liposomes,
with the consequent release of the therapeutic compounds. Additionally, authors have hy-
pothesized that GNRs could also play a role in reducing the signaling of Toll-like receptor-4
(TLR-4) and TLR-9, decreasing NF-κB signaling and subsequently reducing inflammation.
In a murine AIA model, the i.v. injection of targeted liposomal formulation combined with
laser irradiation resulted in the most significant decrease of paw edema, arthritis score and
inflammatory cells infiltration [120]. Moreover, proinflammatory cytokine levels were also
reduced and enhanced cartilage protection was observed with this treatment in comparison
with all the other groups—free dexamethasone; folate-targeted liposomes with dexametha-
sone; the mixture of ODNs and GNRs with laser irradiation; folate targeted liposomes with
GNRs and ODNs combined with laser irradiation; and non-targeted liposomes with the
three compounds—demonstrating the potential of combined approaches in RA therapy.
4.1.6. Liposomes Containing Nonconventional Compounds
Some compounds that do not fall into the four main classes of therapeutic agents used
in RA treatment, such as natural compounds and products used in traditional Chinese
medicine, have also been investigated. An example is a thermosensitive liposomal formula-
tion (PDI: 0.2, ζ: −4 mV, E.E.: 95–98%) with sinomenine hydrochloride that is released after
microwave hyperthermia [59]. A temperature surge (localized hyperthermia) was then
used as a trigger for sinomenine release from liposomes leading to a higher therapeutic
effect when compared to free sinomenine or to hyperthermia alone. In this study, the higher
therapeutic effect was translated in the reduction of paw edema and arthritis scores, along
with decreased proinflammatory cytokine levels, synovial inflammation and bone erosion.
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Part of the research involving new compounds also takes advantage of active targeting
to further enhance the treatment outcome. Such examples are conventional mannose-
targeted liposomes incorporating morin, p-coumaric acid or withaferin-A and PEG-liposom-
es containing core peptide, targeted with RGD or HAP-1 peptides—see Table 1 [78,86,87,
102]. All these nanocarriers demonstrated an improved therapeutic benefit in an AIA
rat model, where the following effects were observed: (i) reduction of paw edema; (ii)
downregulation of proinflammatory cytokines; (iii) suppression of inflammatory cells
infiltration; (iv) minimization of cartilage damage and (v) decreased or inexistent bone
erosion. Additionally, some other factors were investigated in some of the studies, including
the survival probability that was increased in the case of core peptide liposomes targeted
with RGD or HAP-1; the production of ROS and nitric oxide and the RA-induced loss
of body weight that decreased upon treatment with mannose-targeted liposomes with
morin, p-coumaric acid or withaferin-A. Interestingly, a comparison among some of these
nanoDDS with liposomes containing a conventional drug was also performed, where it
was observed that mannose-targeted liposomes that contained morin (ζ: −54 mV, E.E.:
83–90%) exerted a similar therapeutic effect than the ones containing dexamethasone, with
the exception of joint damage, that was further reduced with the morin formulation [86].
Mannose-targeted liposomes with incorporated withaferin-A (PDI: 0.1, ζ: −49 mV) were
also compared to ones containing dexamethasone, and the results demonstrated that they
have similar effects, except for paw edema, cartilage damage and anti-inflammatory marker
expression, where liposomal withaferin-A caused a higher reduction in the first two and a
higher expression of the third [87].
Another example is the mannose-targeted liposomal formulation with p-coumaric
acid (PDI: 0.1, ζ: −56 mV, E.E.: 95%) that was compared to similar liposomes containing
methotrexate. Generally, the therapeutic effect was similar, but animals showed greater
balance on the beam walk test when treated with p-coumaric acid liposomes [102]. A direct
comparison was also performed with liposomes containing core peptide (PDI: <0.4, ζ: −16
to −24 mV) or prednisolone, targeted with RGD or HAP-1 peptides. In this study [78],
the liposomal formulation with p-coumaric acid and HAP-1 peptide demonstrated the
highest therapeutic effectiveness in RA since it enabled a dose-reduction combined with
significant and long-term suppression of the inflammation in arthritic rats. Moreover, the
targeting with HAP-1 peptide demonstrated better results than RDG when used with both
compounds, allowing their dose reduction. From these two results is possible to conclude
that HAP-1 targeting appears to be a better targeting agent from RA and that core peptide
could be a good possibility for liposomal drug delivery in RA treatment.
The previously presented systems for nonconventional compounds were studied
upon i.v. administration. However, other routes have also been investigated, namely
transdermal and oral, that usually have improved patient compliance in comparison to
injectable routes. The transdermal route has been used to administer liposomes (E.E.: 88%)
with triptolide—a compound used in traditional Chinese medicine for RA—that were
loaded into a hydrogel patch [60]. The systemic delivery of these liposomes was enhanced
using a micro-needle array that promoted transdermal absorption. The three liposomal
triptolide doses evaluated were able to reduce joint swelling and decrease proinflammatory
cytokines in a dose-dependent manner, but all resulted in an improved therapeutic outcome
in comparison to non-treated arthritic rats.
Oral administration was explored to deliver coenzyme Q10—an antioxidant used in
dietary supplements—in a hybrid system involving liposomes and gold particles [129].
Treatment of a murine CIA model with this nanocarrier resulted in a higher decrease in
proinflammatory cytokines, cartilage damage and bone erosion in comparison to oral Q10,
demonstrating the therapeutic potential that known dietary supplements could exert when
properly formulated.
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5. Translation to the Clinic
5.1. Clinical Trials with Drug Delivery Nanosystems in Rheumatoid Arthritis
Many clinical trials involving RA are already in development. A search for RA
treatments at the USA National Library of Medicine database (https://www.clinicaltrials.
gov, accessed on 17 February 2021) shows 2595 clinical trials, and the European Union
Clinical Trials Register (https://www.clinicaltrialsregister.eu/, accessed on 17 February
2021) shows 798 clinical trials, either finished or still ongoing. Most of these clinical trials,
especially the ones in phases III and IV, include either synthetic or biological drugs. In
both databases were only reported seven studies involving drug delivery nanosystems, as
indicated in Table 2.
Table 2. Drug delivery nanosystems currently in clinical trials for rheumatoid arthritis treatment.




containing prednisolone NCT00241982 (phase II) and NCT02534896 (phase III)








The percentage of nanoDDS in the clinical trials identified for RA treatment is currently
less than 1%, clearly demonstrating that there is still a long way before the successful clinical
translation of nanoDDS for this pathology, with the focus still remaining on conventional
or biologic drugs. Nevertheless, in the last decade, several gene therapy products have
entered the market [137], reinforcing the investigation on nanoDDS for gene therapy that
resulted in active clinical trials with viral vectors for RA treatment. Furthermore, it is
possible to observe that the trials in the most advanced phases are liposomal formulations,
indicating that more recent technologies could be facing difficulties in moving beyond the
preclinical stages.
5.2. Transition of Drug-Delivery Nanosystems to the Market
With nanoDDS is possible to enhance compounds therapeutic index, either through
the improvement of drugs pharmacokinetic or pharmacodynamic properties (e.g., carriers
protect drugs from early degradation and enable them to cross biologic barriers more easily);
the direct delivery to a specific target and the minimization of severe side-effects [51,52]. If
properly applied, delivery systems have the potential to exert a major impact on human
health. Nonetheless, there are only a limited number of nanocarriers in clinical trials and,
even fewer, in the market. This fact highlights the discrepancy existent between nanoDDS
with promising results in preclinical stages and the ones that demonstrated therapeutic
potential in the clinical setting [138]. Indeed, currently, no nanoDDS received market
approval for RA treatment, despite all the encouraging results reported in Section 4.
Clear identification of the main factors responsible for the inefficient clinical transla-
tion of nanoDDSs must be performed to avoid the same errors, improving their translation
to successful clinical trials and, ultimately, to the market. Such obstacles prevent the full
impact and translation of nanoDDS into clinically feasible therapies, among which are
the difficulties in the preclinical characterization of nanosystems, in their scale-up pro-
duction to an industrial level and the evaluation of their in vivo pharmacokinetics and
pharmacodynamics properties. Additionally, safety evaluation could be more difficult
with these new carriers, and, frequently, they are not developed in compliance with good
manufacturing practice (GMP) regulations [55,139]. The slowness of the process itself and
the high-cost for the pharmaceutical industry also hinder nanosystem clinical translation.
The latter is even more important in the case where nanoDDS are used with approved
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drugs—which is the case of most of the currently marketed formulations—since the indus-
try would possibly invest even more than in the original drug approval process because
the required techniques are frequently more complex and is necessary to repeat all the
studies (e.g., efficacy and toxicity) for nanocarriers approval, due to their distinct pharma-
cokinetic and biodistribution profiles from the original drugs [51,140]. The inexistence of
guidelines specific for nanosystems that are equivalent for all the regulatory agencies is
another critical factor that negatively affects market authorizations, especially for products
that combine several therapies and/or technologies, such as theranostic agents [141,142].
A more detailed description of the aforementioned factors can be consulted in Germain
et al. [55] and Taha et al. [143].
Taking all these factors into consideration during the development stages of nanoDDS
may potentially result in improved clinical translation. An example is the development of
systems following GMP guidelines to guarantee consistent quality, using biocompatible
starting materials and techniques that allow robust and scalable manufacturing to facilitate
the commercialization process [139,143]. Moreover, the new therapy should be compared
with the gold standard used in the clinic [138,141]. In RA, the treatment regimen is highly
dependent on the patient’s reaction to each therapy, and, frequently, drugs from several
classes are used simultaneously, which hamper the proper evaluation of a nanocarrier
therapeutic value.
Nanocarrier complexity is another barrier that has slowed their translational suc-
cess. For this reason, investigators should avoid highly complex designs, such as the
one described by Xue et al. [120], when developing nanoDDS, since it will simplify the
manufacture and characterization processes, improving the large-scale reproducibly and
reducing the final product cost [144,145].
The use of adequate in vitro and in vivo models that more closely resembles the hu-
man physiopathology of the disease can improve predictions of the therapeutic outcome
in humans, especially in the case of chronic diseases [138]. In RA, model selection should
be carefully considered due to the existence of several models that display distinct charac-
teristics [132]. An example of the importance of the in vivo model choice was reported by
Hua et al. Hu [146] in a study with liposomal loperamide that, initially was evaluated in a
CFA model demonstrating the promising anti-inflammatory activity, but afterward was
evaluated in an AIA model—that is more complex and presents more similarity to human
RA—resulting in an enhanced severity of inflammation and in the acceleration of arthritis
progression.
Studies where RA treatment was evaluated using different nanoDDS with the same
therapeutic agent or using distinct drugs in the same nanocarrier—as performed in [73]
and [147], respectively—should also be recommended, since it would enable the direct com-
parison of the therapeutic benefit and the definition of the most promising characteristics
for each drug and delivery system.
Moreover, during initial study planning, treatment schedules should be carefully
planned considering the disease specificities. For instance, prophylactic treatment or
treatment where the therapy starts shortly after RA onset will hardly produce useful results
because RA is not possible to predict, and there is an interval between the beginning of
symptoms, the adequate diagnostic, and the medical treatment. The administration route
used in the studies also has an important role, since when possible, patient compliance
should be maximized (e.g., by avoiding injectable routes), and the use of large injection
volumes should be avoided—it would imply increasing medical costs, decreasing the
cost-effectiveness of the nanocarrier [143].
In inflammatory diseases, it is of utmost importance to consider its specificity in terms
of the inflammatory profile, a factor that is lacking in many studies and is partially respon-
sible for the insufficient preclinical success and clinical translation. In RA, despite joints
being the principal affected area, inflammatory mediators are systemically transported.
Due to this characteristic, using exclusively an active targeting approach or a carrier that
only exhibited a local effect is not the most advisable since it would result in a limited
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therapeutic effect. In this case, developing a nanoDDS—either alone or as a combined
therapy—that could tackle the local and systemic inflammation would be preferable. Addi-
tionally, since RA is a chronic inflammatory process where inflammation is continuously
perpetuated, a system that enabled a more prolonged therapeutic effect would be desirable.
Besides all these aspects, the collaboration between academia, clinicians, experts from
all stages of pharmaceutical development and regulatory authorities must continue to
create standardized protocols and uniform regulations worldwide that will increase the
number of nanoDDS successfully translated into the market [145,148].
6. Conclusions
From the wide panoply of inflammatory diseases, the chronic type is a major concern
since it is associated with the permanent disability of patients and to severe socioeconomic
problems due to the high costs, both for therapy and care. A special focus should be
attributed to RA due to its large worldwide prevalence. Despite the multiple therapies
available for this pathology, currently, there is no cure, and each therapy presents side-
effects that are very important due to long-term use. NanoDDS, such as liposomes, enclose
a great therapeutic potential due to their ability to minimize side effects and to enable a
specific delivery to a target site and a controlled drug release. However, the encouraging
results obtained with multiple carriers in preclinical studies only resulted in three clinical
trials with liposomal formulations and four with viral vectors and no market approval
granted to any treatment. The failure in translating the success obtained in preclinical
studies to clinical trials due to the inefficient active targeting effect in humans and the lack
of specific and uniform regulations are the factors that should be addressed to enhance
nanoDDS clinical translation. However, since these drawbacks have been surpassed in
other diseases, the same will potentially occur, resulting in nanocarriers’ approval for RA
treatment in the clinic.
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good manufacturing practice; GNRs—gold nanorods; HSPC—hydrogenated soybean phosphatidyl-
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SDS—sodium dodecyl sulfate; SL—soybean lecithin; SM—porcine brain sphingomyelin; SOD—
superoxide dismutase; SPC—soybean phosphatidylcholine; SUVs—small unilamellar vesicles; S100—
poly(ethyleneglycol) (100) monostearate; TLR—Toll-like receptor; TNF—tumor necrosis factor; TNF-
α—tumor necrosis factor-alpha; VEGF—vascular endothelial growth factor; ζ—superficial charge.
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